The CML Guide
Information for Patients and Caregivers
Printing of this publication made
possible by a grant from
CHRONIC MYELOGENOUS LEUKEMIA
A Message from John Walter
President and CEO of The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society (LLS) is committed to
bringing you the most up-to-date blood cancer information.
We know how important it is for you to have an accurate
understanding of your diagnosis, treatment and support
options. With this knowledge, you can work with members
of your oncology team to move forward with the hope of
remission and recovery.
Outcomes for people with chronic myelogenous leukemia
(CML) are dramatically improved compared to what they
were just a decade ago; this progress comes from newer
therapies. Our vision is that one day the great majority of
people who have been diagnosed with CML will be cured or
that people with all phases of CML will be able to manage
their illness with good quality of life. We hope the information
in this booklet will help you along your journey.
LLS is the world’s largest voluntary health organization
dedicated to funding blood cancer research, education and
patient services. Since its founding in 1949, LLS has invested
more than $600 million in research specifically targeting blood
cancers. We will continue to invest in research for cures and
in programs and services that improve the quality of life for
people who have CML and their families.
We wish you well.
President and CEO
Chronic myelogenous leukemia (CML) is a type of cancer. The
number of people with CML who are living well is growing. This is
due to new treatments. Three new CML drugs have been approved
since 2001. Other new treatments are being studied in clinical trials.
Progress toward a cure is under way.
Many people want to know what questions to ask their doctor.
They may want information about choosing a specialist or about
treatment. This Guide includes a li